Gelatin-Based Hydrogel Developed for Dual Delivery of ARV-471 and Palbociclib in Breast Cancer Therapy

A recent study has explored the use of a dual-drug codelivery system utilizing a gelatin-based hydrogel to enhance the synergistic effects of ARV-471 and Palbociclib in breast cancer treatment. Researchers investigated the combination therapy’s potential to improve therapeutic outcomes by targeting specific pathways involved in cancer progression. The study focused on the development and application of this hydrogel-based delivery system, aiming to optimize drug release and efficacy.

The research detailed how the gelatin-based hydrogel was designed to simultaneously deliver ARV-471, an oral selective estrogen receptor degrader (SERD), and Palbociclib, a cyclin-dependent kinase 4/6 inhibitor. This approach aimed to maximize the drugs’ combined anti-cancer effects while minimizing side effects associated with traditional delivery methods. The study demonstrated that this dual-drug delivery system enhanced cellular uptake and improved drug stability, leading to increased effectiveness against breast cancer cells in preclinical models. Findings suggest that this innovative method may provide new insights into combination therapies for breast cancer treatment.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 29, 2025

Related posts:

Pharmaceutical Investments Eye Generic Drug Market as Patents Expire, Opening Doors for Competition and Innovation. Health Secretary Robert F. Kennedy Jr. Dismisses Entire CDC Vaccine Advisory Panel Trump Extends Tariffs on Foreign Drugs and Furniture Citing National Security Laws Premature Mortality Among US Adults Aged 18 to 64 Increased by Over 27 Percent Between 2012 and 2022

Author

GOAI